Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

Bristol Myers Squibb and UbiVac have collaborated to assess combination immunotherapy for advanced triple negative breast cancer. (Credit: Rept0n1x)